Assessment of Prospective Real-world Outcomes Based on Single-patient Protocol Data Collection of Afatinib (GILOTRIF®) Use in Patients With Solid Tumors Harboring NRG1 Gene Fusions

Inclusion Criteria to participate in this program:

* Confirmed diagnosis of an advanced, unresectable and/or metastatic tumor harboring NRG1 gene fusions characterized as follows:

* Gene 1: NRG1 (prerequisite: conservation of the epidermal growth factor (EGF) domain - this will be identified by the lab performing the molecular testing)

* Gene 2: All fusion partners are allowed (prerequisite: the region must be a coding region - this will be identified by the lab performing the molecular testing)

* Patient must have measurable or evaluable lesions (according to RECIST 1.1).

* At least 18 years of age at the time of consent.

Exclusion Criteria:

* Treatment with a systemic anti-cancer therapy or investigational drug within 14 days or 5 half-lives (whichever is shorter) of the first treatment with the study medication.

* Tumors carrying additional gene mutations other than NRG1 fusion where FDA-approved targeted therapy is available

* Prior treatment with a therapy targeting erythroblastic leukemia viral oncogene homologue receptors (ErbB)

* Any patient considered ineligible by the treating physician.